Treatment of Small Intestinal Bacterial Overgrowth (SIBO) in Gastrointestinal, Hepatic, Endocrine, Neurological, and Postoperative Diseases: A Comprehensive Narrative Review - PubMed
3 hours ago
- #antibiotics
- #probiotics
- #SIBO treatment
- SIBO is an abnormal bacterial overgrowth in the small intestine associated with various diseases and postoperative states.
- Rifaximin is the most studied drug, eliminating SIBO in 63% of cases, but evidence from RCTs is conflicting and lacks large-scale validation.
- Other antibiotics like neomycin and norfloxacin show efficacy in single RCTs, with elimination rates of 20% and 100% respectively.
- Probiotics such as VSL#3 and Saccharomyces boulardii CNCM I-745 demonstrated effectiveness in RCTs, with elimination rates of 58% and 80%.
- Treatment selection should prioritize regimens with the highest efficacy for specific concomitant diseases, despite generally low evidence levels.